Episode Details

Eton Pharmas Q1 2026 earnings are scorching hot, with product sales surging 73% to $24 million and total revenue reaching $24.3 million. Theyre raising full-year guidance to over $120 million, driven by strong performances from Increlex, AlkindI Sprinkle, Galzin, and Carglumic Acid. New launches Desmoda and Hemangeol are off to a promising start, with Desmoda potentially peaking at $30-$50 million annually. Prescribers and families are thrilled with the improvements, and R&D efforts are advancing rapidly, including Increlex label expansion, ET-700 pilot study, and Khindivi and Amglidia for neonatal diabetes. With adjusted EBITDA at $5.7 million and strong cash flow, Eton is on track for a $200 million run rate by 2027.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/beefd41aaccd54be